{"url_path":"/sec/fth/8-k/2026-06-15/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-15","source_url":"https://www.sec.gov/Archives/edgar/data/1829802/0001193125-26-270330-index.html","accession_number":"0001193125-26-270330","cik":"0001829802","ticker":"FTH","issuer_name":"Faeth Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1829802/0001193125-26-270330-index.html","primary_entity_key":"0001829802","primary_entity_name":"Sensei Biotherapeutics, Inc."},"word_count":45,"has_tables":true,"body_markdown":"Item 8.01\n\nOther Events.\n\nEffective June 15, 2026, the Company relocated its principal executive office from 1405 Research Blvd, Suite 125, Rockville, MD 20805, to 701 Tillery Street #12 #1010, Austin, TX 78702. The Company’s telephone number at its new principal executive office is 512-200-2982."}